Stay up to date on the latest oncology and nursing conferences.
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.
Improved Survival Outcomes Are Observed In GI Cancers With Medicaid Expansion
Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.
Minimally Invasive Distal Pancreatectomy Proves Noninferior to Open Distal Pancreatectomy in Resectable Pancreatic Cancer
Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.
Johanna Garibaldi On Strengthening Cancer Prevention Tactics With Mobile Screening Clinics
Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.
Formation of an Oncology Nurse Leader Council Promotes Frontline Nurse Engagement
Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.
Seth Eisenberg Compares the Effectiveness of Plastic-Backed Pads Vs The Splashblocker in Reducing Toilet Aerosols
Seth Eisenberg, ASN, RN, OCN, BMTCN, discusses his research comparing plastic-backed pads and the Splashblocker.
Pattie Jakel Highlights the Challenges With Oral Therapies in Breast Cancer
Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.
Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast Cancer
Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.
Patients With De Novo or Late Recurrent Metastatic HR+ Breast Cancer Derive OS Benefit From Ribociclib/Letrozole
A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.
Kellie Zeichner Speaks to the Power of Standardized Monitoring Procedures for Patients With Rare Tumors
Kellie Zeichner BSN, RN, OCN, explains how her institution created a standardized monitoring procedure for insulinoma care.
Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Olaparib Delivers PFS Benefit to Patients with gBRCA+, HER2– Metastatic Breast Cancer, Independent of ER Status
A post-hoc analysis suggests that olaparib may extend progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level.
Kara Morris and Christine Wylie on Oral Cryotherapy for Chemotherapy-Induced Mucositis in Breast Cancer
Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss the benefits of oral cryotherapy for patients receiving dose-dense doxorubicin.
Trastuzumab Deruxtecan Exhibits Favorable Safety Profile in DESTINY-Breast04 Follow-Up
Trastuzumab deruxtecan outperformed investigators choice of therapy, in terms of safety, among patients with HER2-Low Metastatic Breast Cancer.
Neutropenia and Diarrhea AEs Did Not Impact Clinical Outcomes for Patients with mTNBC Receiving Sacituzumab Govitecan
Using established guidelines to monitor and intervene early for diarrhea and neutropenia may result in longer treatment durations and sustained benefit from sacituzumab govitecan.
Melanie Darvish on Receiving an ONS Scholarship and What it Means to Be An Oncology Nurse
Melanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.
Heath-related QOL Maintained Longer With Trastuzumab Deruxtecan in HER2+ mBC
The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.
Abemaciclib Displays Manageable and Reversible Safety Profile in monarchE PRO Findings for HR+/HER2– Breast Cancer
Patient-reported outcomes demonstrated a manageable safety profile with abemaciclib.
AnnMarie Walton on Reducing Antineoplastic Drug Residue in Inpatient Units
AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN, discusses her research on plastic-backed pads and discusses the importance of better methods to reduce exposure to antineoplastic drug residue.
Enzalutamide Associated With Lower Metastases Risk Vs Leuprolide Alone in High-Risk nmHSPC
Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.
Apalutamide/ADT Shows PFS Improvement in Relapsed Prostate Cancer
Apalutamide plus androgen deprivation therapy (ADT) yielded a progression-free survival of 24.5 months vs 21.0 months with ADT alone.
Low and Maldonado on Leveraging Wearable Devices to Improve Inpatient Ambulation
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.
Heather Niccum Haag on Improving Patient Education With Belzutifan
Heather Niccum Haag, BSN, RN, CCRN, shares her experience creating an educational resource for her patients with Von-Hippel Lindau tumors who are receiving belzutifan.
Bisphosphonates May Reduce Fracture Risk in Patients With Metastatic Hormone-Sensitive Prostate Cancer
A database analysis showed that zoledronic acid led to a 64% reduction in fracture risk among patients with metastatic hormone-sensitive prostate cancer.
Nivolumab Following Radical Surgery Extends Disease-Free Survival Rates in Bladder Cancer
Nivolumab bested placebo in improving disease-free survival rates in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.
Gene Therapy Agent URO-902 Shows Promise in Helping Woman Manage Overactive Bladder and Urinary Incontinence
Phase 2a trial data suggest that single-dose URO-902 may be an effective, and safe, treatment for women experiencing difficulties with bladder control.
Elizabeth Loach on Integrating Frontline Staff in Nursing Task Forces
Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, discusses the importance of including frontline nurses in nursing leadership task forces.
Splashblocker Shows Promise in Reducing Spread of Hospital Toilet Contaminants
The Splashblocker was found to be an effective way to reduce contaminated particles. Plastic backed pads had mixed reviews.
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer